Statin Continuation After an Index Hospitalization for Hepatic Decompensation in MASLD Cirrhosis

BACKGROUND: Whether established statin therapy should be continued after hospitalization for hepatic decompensation in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis remains uncertain. METHODS: We performed a retrospective multicenter cohort study in the TriNetX Research network. Adults aged 18-75 years with MASLD cirrhosis, a qualifying inpatient decompensation event, and a statin record before index were classified by whether a statin was recorded from the index date through day 30. Propensity score matching was used to improve balance across demographics, comorbidities, liver-related features, medications, and laboratory values. Outcomes were evaluated through 1 year using platform-generated survival analyses. RESULTS: The matched analysis included 1,108 patients (554 per group). At 1 year, statin continuation was not associated with the subsequent decompensation composite (62.1% vs 61.6%; HR 1.08, 95% CI 0.93-1.26) or all-cause mortality (19.7% vs 19.5%; HR 1.04, 95% CI 0.80-1.36). Subsequent ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, the cardiovascular composite, and the muscle and laboratory liver injury composites also did not differ. Liver transplantation was less frequent (2.3% vs 6.1%; HR 0.38, 95% CI 0.20-0.73), whereas all-cause hospitalization was more frequent (62.6% vs 57.8%; HR 1.20, 95% CI 1.03-1.40). Exploratory high-intensity analyses showed higher decompensation, hepatic encephalopathy, and hospitalization. CONCLUSIONS: Among prevalent statin users with MASLD cirrhosis, continuation after an index decompensation hospitalization was not associated with lower 1-year decompensation or mortality. Isolated secondary and intensity findings are exploratory. Residual confounding, exposure misclassification, competing risk, and overlap between exposure classification and early follow-up limit causal interpretation; prospective and time-aligned studies are needed.

Authors

Institutions

Publication Details

Journal
Digestive Diseases and Sciences
Published
2026-09-08
DOI
https://doi.org/10.1007/s10620-026-10236-w
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Statin Continuation After an Index Hospitalization for Hepatic Decompensation in MASLD Cirrhosis

Akram Alnounou, Bisher Sawaf, Mohammad Alabbas, EzzElDien A. Ibrahim et al.
Digestive Diseases and Sciences
Liver Disease Diagnosis and Treatment
article

Statin Continuation After an Index Hospitalization for Hepatic Decompensation in MASLD Cirrhosis

Akram Alnounou, Bisher Sawaf, Mohammad Alabbas, EzzElDien A. Ibrahim, Abdulrahman M. Karam, Barbara Balog, Basile Njei
article en

Abstract

BACKGROUND: Whether established statin therapy should be continued after hospitalization for hepatic decompensation in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis remains uncertain. METHODS: We performed a retrospective multicenter cohort study in the TriNetX Research network. Adults aged 18-75 years with MASLD cirrhosis, a qualifying inpatient decompensation event, and a statin record before index were classified by whether a statin was recorded from the index date through day 30. Propensity score matching was used to improve balance across demographics, comorbidities, liver-related features, medications, and laboratory values. Outcomes were evaluated through 1 year using platform-generated survival analyses. RESULTS: The matched analysis included 1,108 patients (554 per group). At 1 year, statin continuation was not associated with the subsequent decompensation composite (62.1% vs 61.6%; HR 1.08, 95% CI 0.93-1.26) or all-cause mortality (19.7% vs 19.5%; HR 1.04, 95% CI 0.80-1.36). Subsequent ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, the cardiovascular composite, and the muscle and laboratory liver injury composites also did not differ. Liver transplantation was less frequent (2.3% vs 6.1%; HR 0.38, 95% CI 0.20-0.73), whereas all-cause hospitalization was more frequent (62.6% vs 57.8%; HR 1.20, 95% CI 1.03-1.40). Exploratory high-intensity analyses showed higher decompensation, hepatic encephalopathy, and hospitalization. CONCLUSIONS: Among prevalent statin users with MASLD cirrhosis, continuation after an index decompensation hospitalization was not associated with lower 1-year decompensation or mortality. Isolated secondary and intensity findings are exploratory. Residual confounding, exposure misclassification, competing risk, and overlap between exposure classification and early follow-up limit causal interpretation; prospective and time-aligned studies are needed.

Digestive Diseases and Sciences
Cleveland Clinic (US), University of Debrecen (HU), Western Michigan University (US), Cornell University (US), Cleveland Foundation (US), Yale University (US), Presbyterian Hospital (US), Stryker (United States) (US), University of Missouri (US), University of Toledo (US)
Zero hunger
Openalex Percentile: Top 10%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.